Paromomycin sulfate: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{Paromomycin sulfate}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
Paromomycin is an [[aminoglycoside]] antibiotic, first isolated from ''Streptomyces krestomuceticus'' in the 1950s.<ref name="Davidson2008">{{cite journal| author = Davidson R.N., den Boer M., Ritmeijer K. | year = 2008 | title = Paromomycin | journal = Transactions of the Royal Society of Tropical Medicine and Hygiene | volume = 103| issue = 7| pages = 653–60| doi = 10.1016/j.trstmh.2008.09.008| pmid = 18947845}}</ref> It was discovered by [[Parke Davis]] now [[Pfizer]] and introduced as ''Humatin'' in 1960.<ref>Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false</ref> It is also called monomycin and aminosidine.<ref name="Neal1994">{{cite journal |author= Neal R.A. ''et al''. |year=1994 |title=Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis |journal=Transactions of the Royal Society of Tropical Medicine and Hygiene |volume=88 |issue=2 |pages=223–5 | doi=10.1016/0035-9203(94)90307-7 |pmid= 8036682 }}</ref> | |||
==Category== | |||
Amebicide | |||
==US Brand Names== | |||
PAROMOMYCIN SULFATE capsule<sup>®</sup> | |||
Paromomycin | ==FDA Package Insert== | ||
'''[[Paromomycin sulfate description|Description]]''' | |||
'''| [[Paromomycin sulfate clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Paromomycin sulfate microbiology|Microbiology]]''' | |||
'''| [[Paromomycin sulfate indications and usage|Indications and Usage]]''' | |||
'''| [[Paromomycin sulfate contraindications|Contraindications]]''' | |||
'''| [[Paromomycin sulfate warnings|Warnings]]''' | |||
'''| [[Paromomycin sulfate precautions|Precautions]]''' | |||
'''| [[Paromomycin sulfate adverse reactions|Adverse Reactions]]''' | |||
'''| [[Paromomycin sulfate overdosage|Overdosage]]''' | |||
'''| [[Paromomycin sulfate clinical studies|Clinical Studies]]''' | |||
'''| [[Paromomycin sulfate dosage and administration|Dosage and Administration]]''' | |||
'''| [[Paromomycin sulfate compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | |||
'''| [[Paromomycin sulfate directions for use|Directions For Use]]''' | |||
'''| [[Paromomycin sulfate how supplied|How Supplied]]''' | |||
'''| [[Paromomycin sulfate other size packages available|Other Size Packages Available]]''' | |||
'''| [[Paromomycin sulfate labels and packages|Labels and Packages]]''' | |||
==Mechanisms of Action== | |||
Paromomycin is a [[protein synthesis inhibitor]] in non-resistant cells by binding to [[16S ribosomal RNA|16S]] [[ribosomal RNA]].<ref>{{cite journal | |||
| last = Vicens | first = Quentin | coauthors = Eric Westhof | | last = Vicens | first = Quentin | coauthors = Eric Westhof | ||
| year = 2001 | month = August | | year = 2001 | month = August | ||
| title = Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site | journal = Structure | | title = Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site | journal = Structure | ||
| volume = 9 | issue = 8 | pages = | | volume = 9 | issue = 8 | pages = 647–658 | ||
| doi = 10.1016/S0969-2126(01)00629-3 | | | doi = 10.1016/S0969-2126(01)00629-3 | pmid = 11587639 | ||
| url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5 | | url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5 | ||
| accessdate = 2007-02-10 | | accessdate = 2007-02-10 | ||
}}</ref> | }}</ref> This broad spectrum antibiotic soluble in water, is very similar in action to [[Neomycin]]. Antimicrobial activity of Paromomycin against [[Escherichia coli]] and [[Staphylococcus aureus]] has been shown.<ref>{{ cite web | title = Paromomycin | url = http://www.toku-e.com/Upload/Products/PDS/20120518007094.pdf | format = pdf | publisher = Toku-E | date = 2010-01-12 | accessdate = 2012-06-11 }}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{ | |||
[[ | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | |||
Revision as of 20:25, 23 December 2013
Paromomycin Sulfate |
---|
PAROMOMYCIN SULFATE capsule® FDA Package Insert |
Description |
Clinical Pharmacology |
Indications and Usage |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Dosage and Administration |
How Supplied |
Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Paromomycin is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in the 1950s.[1] It was discovered by Parke Davis now Pfizer and introduced as Humatin in 1960.[2] It is also called monomycin and aminosidine.[3]
Category
Amebicide
US Brand Names
PAROMOMYCIN SULFATE capsule®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages
Mechanisms of Action
Paromomycin is a protein synthesis inhibitor in non-resistant cells by binding to 16S ribosomal RNA.[4] This broad spectrum antibiotic soluble in water, is very similar in action to Neomycin. Antimicrobial activity of Paromomycin against Escherichia coli and Staphylococcus aureus has been shown.[5]
References
- ↑ Davidson R.N., den Boer M., Ritmeijer K. (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene. 103 (7): 653–60. doi:10.1016/j.trstmh.2008.09.008. PMID 18947845.
- ↑ Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false
- ↑ Neal R.A.; et al. (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (2): 223–5. doi:10.1016/0035-9203(94)90307-7. PMID 8036682.
- ↑ Vicens, Quentin (2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure. 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved 2007-02-10. Unknown parameter
|month=
ignored (help); Unknown parameter|coauthors=
ignored (help) - ↑ "Paromomycin" (pdf). Toku-E. 2010-01-12. Retrieved 2012-06-11.